Abstract Library

#4247 Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia - A case report

Introduction: Idiopathic Diffuse Neuroendocrine Diffuse Neuroendocrine Hyperplasia is a rare, but increasingly recognized entity that primarily affects middle-aged and elderly women, Of available therapies, somatostatin analogs and mTOR are the most promising

Conference:

Presenting Author: Florez A

Authors: Florez A, Unigarro M, Fernandez J, Viola L, Perez G,

Keywords: neuroendocrine tumor, lung, idiopathic diffuse neuroendocrine hyperplasia, tumorlets,

#3305 177Lu-Dotatate efficacy and safety in functioning neuroendocrine tumors: A joint analysis of phase 2 prospective clinical trials

Introduction: Neuroendocrine tumors are a rare neoplasia. At least 25% of patients (pts) with advanced disease may have functioning neuroendocrine tumors (F-NETs) that can secrete bioactive peptides that can lead to specific symptoms like diarrhea that can be debilitating and life-threatening.Although symptom relief is available with somatostatin analogs (SSA), the disease eventually becomes refractory to SSA,leaving no proven treatment options

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Bongiovanni A

Authors: Bongiovanni A, Nicolini S, Ibrahim T, Foca F, Sansovini M,

Keywords: neuroendocrine tumor, carcinoid syndrome, neuroendocrine neoplasia, PRRT, insulinoma, 177Lu-Dotatate, functioning tumor,

#3075 Telotristat Makes Significant Difference on Symptoms and Serotonin Levels in a Population with Widespread GI-NET and Severe Carcinoid Syndrome

Introduction: In spite of new treatments like PRRT or everolimus there is a clinical need for systemic therapies that complement SSAs (somatostatin analogs) and antidiarrheal agents in the treatment of carcinoid syndrome, a late stage problem in s-i-NET. Telotristat is a promising addition to our therapeutic arsenal.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Linder Ekberg K,

Keywords: telotristat, carcinoid syndrome, metastasized GI-NET,

#3067 Somatostatin Analogs in Real‐World Practice for Patients with Metastatic Neuroendocrine Tumors: A Single Institution Experience in the Ouest of Algeria (CHU Oran)

Introduction: The efficacy of somatostatin analogs (SSAs) were clearly established trough pivotal trials as first‐line agents for neuroendocrine tumors (NETs), but their use in clinical practice is largely unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ameziane N, Behourah Z, Aida M, Ahed Messaoud M, Bousahba A,

Keywords: GEP-NET, Somatostatin analogs, anti proliferative action, anti secretory action, Management real world practice,

#3055 Dynamics of Changes in Chromogranin A Concentration as a Prognostic Factor Radiopeptide Therapy in Neuroendocrine Tumours

Introduction: Chromogranin A (CgA) is a non-specific marker of neuroendocrine tumors (NET) and its significantly increased level is an unfavorable prognostic factor while the decrease in CgA during biotherapy with somatostatin analogs (SSA) correlates with the increase in profession free survival (PFS).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Sygula A, Jurecka-Lubieniecka B, Hasse-Lazar K, Michalik B, Ledwon A,

Keywords: CgA, PRRT, prognosis,